The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: A review of rtPA neurotoxicity
Alteplase is the only drug licensed for acute ischemic stroke, and in this formulation, the thrombolytic agent recombinant tissue plasminogen activator (rtPA) is stabilized in a solution of L-arginine. Improved functional outcomes after alteplase administration have been shown in clinical trials, al...
Main Authors: | Harston, G, Sutherland, B, Kennedy, J, Buchan, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.
by: Harston, G, et al.
Published: (2010) -
The neurotoxicity of tissue plasminogen activator?
by: Kaur, J, et al.
Published: (2004) -
Intracameral recombinant tissue plasminogen activator (rtPA) as the primary treatment for secondary pupillary block
by: AR, Siti Noor Atikah, et al.
Published: (2022) -
Is glucose a predictor of hemorrhage after rtPA therapy in acute stroke?
by: Demchuk, A, et al.
Published: (1998) -
Growth differentiation factor-11 causes neurotoxicity during ischemia in vitro
by: Sutherland, BA, et al.
Published: (2020)